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Dopamine replacement with levodopa (L-DOPA) represents the mainstay of Parkinson’s disease (PD) therapy. Nevertheless, this well
established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidating side effects,
known in their complex as L-DOPA-induceddyskinesia (LID).Unfortunately, existing therapies fail to prevent LID and very fewdrugs are
available to lessen its severity, thus representing amajor clinical problem inPD treatment.D2-like receptor (D2R) agonists are apowerful
clinical option as an alternative to L-DOPA, especially in the early stages of the disease, being associated to a reduced risk of dyskinesia
development. D2R agonists also find considerable application in the advanced stages of PD, in conjunctionwith L-DOPA,which is used in
this context at lower dosages, to delay the appearance and the extent of themotor complications. In advanced stages of PD, D2R agonists
are often effective in delaying the appearance and the extent ofmotor complications. Despite the great attention paid to the family of D2R
agonists, themain reasons underlying the reduced risk of dyskinesia have not yet been fully characterized. Here we show that the striatal
NMDA/AMPAreceptor ratio and theAMPAreceptor subunit compositionare altered in experimental parkinsonism in rats. Surprisingly,
while L-DOPA fails to restore these critical synaptic alterations, chronic treatmentwith pramipexole is associated not onlywith a reduced
risk of dyskinesia development but is also able to rebalance, in a dose-dependent fashion, the physiological synaptic parameters, thus
providing new insights into the mechanisms of dyskinesia.
Introduction
The treatment of Parkinson’s disease (PD) is a major clinical
challenge. Despite therapeutic advances, PD still leads to severe
disability and reduced quality of life (Lees et al., 2009; Jenkinson
et al., 2012).
Thecentralpillar inPDclinicalpractice remains, after almosthalf
century since its introduction, levodopa [L-3,4-dihydroxyphenyl
alanine (L-DOPA)], a dopamine (DA) precursor (Birkmayer
and Hornykiewicz, 1998; Olanow et al., 2006). However, over
time, L-DOPA treatment leads to the emergence of invalidat-
ing motor side effects, such as L-DOPA-induced dyskinesia
(LID) (Obeso et al., 2000; Ahlskog and Muenter, 2001). The
mechanisms underlying LID appear complex and not fully
understood (Calabresi et al., 2008; Fisone and Bezard, 2011).
Thus, the prevention of LID is still a major clinical problem
(Gottwald and Aminoff, 2011; Blandini and Armentero,
2012). Among the numerous players involved in the progres-
sive appearance of LID, abnormal striatal glutamatergic trans-
mission exerts a critical role (Calabresi et al., 2010). This has
been demonstrated in experiments showing that targeting of
striatal glutamatergic transmission can influence LID, which
is associated with altered trafficking of NMDA receptor
(NMDAR) subunits (Gardoni et al., 2006, 2012; Varanese et
al., 2010; Ahmed et al., 2011). In addition to glutamatergic
dysfunction, abnormal activation of D1-like receptors (D1Rs)
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is crucial for LID induction (Feyder et al., 2011). Increased
localization of D1Rs at the cell surface, caused by impaired
receptor internalization and trafficking, is associated with LID
(Guigoni et al., 2007; Berthet et al., 2009). Pharmacological or
genetic inactivation of D1R reduces LID and decreases the
associated molecular alterations (Jenner, 2008; Darmopil et
al., 2009; Voon et al., 2009; Cenci and Konradi, 2010; Lebel et
al., 2010). However, at present, drugs targeting glutamatergic
transmission and D1R signal transduction either produce un-
satisfactory results or are not clinically tolerated.
Great attention has been paid to the development of D2-like
receptor (D2R) agonists as a possible alternative to L-DOPA.
These agonists constitute a powerful clinical option, showing sev-
eral advantages, such as direct receptor stimulation without met-
abolic modifications (required for L-DOPA) and prolonged
pharmacological action (Rascol et al., 2011). They can signifi-
cantly alleviatemotor symptoms in de novoPD, be used asmono-
therapy, particularly in young patients, and can reduce the risk
for developing dyskinesia thanks to longer half-lives compared
with L-DOPA’s pulsatile effects (Hauser et al., 2007; Watts et al.,
2010; Jenner et al., 2011; Calandrella and Antonini, 2012). Addi-
tionally, D2 agonists, when administered as adjunctive therapy to
L-DOPA in the advanced stages of PD, delay the appearance and
the extent of the serious motor complications induced by
L-DOPA (Rinne et al., 1998; Rascol et al., 2000).
However, the synaptic andmolecularmechanisms underlying
the action of D2 agonists have never been fully understood, de-
spite their widespread clinical use. Here, using a combined be-
havioral and cellular approach, we show that in experimental
parkinsonism the NMDAR/AMPA receptor (AMPAR) ratio and
the composition of both NMDAR and AMPAR subunits are al-
tered in striatal spiny neurons. Surprisingly, while L-DOPA fails
to restore these critical synaptic alterations, chronic treatment
with the D2R agonist pramipexole rebalances, in a dose-
dependent fashion, these physiological parameters, thus provid-
ing new insights into the mechanisms of dyskinesia.
Materials andMethods
Animals. AdultmaleWistar rats (150–250 g)were used for the study (n
280). All experiments were approved by the European Communities
Council Directive of November 1986 (86/609/ECC), and by the Italian
Health Ministry.
Nigrostriatal lesion. Male Wistar rats were deeply anesthetized with
chloral hydrate (400 mg/ml/kg; n  260) and were injected with
6-hydroxydopamine (6-OHDA, 12 g/4 l of saline containing 0.1%
ascorbic acid) via aHamilton syringe into themedial forebrain bundle, at
a rate of 0.38 l/min [anteroposterior  4.4; lateral  1.2; ventro-
dorsal7.8] (Fig. 1). Control rats (n 10) were injected with vehicle
at the same coordinates. Fifteen days later, the rats were tested with a 0.05
mg/kg subcutaneous injection of apomorphine, and the contralateral
turns were counted with automatic rotometers for 40 min. Only those
rats consistently making at least 200 contralateral turns (Schwarting and
Huston, 1996) were used for the electrophysiological recordings per-
formed 45 d later (2 months after the lesion), to avoid possible interfer-
ence of apomorphine treatment with the plastic changes occurring inDA
D2 receptor function following chronic dopaminergic denervation. The
severity of the lesion was also quantified afterward by striatal and nigral
TH immunohistochemistry (data not shown).
Behavioral testing of motor deficits, stepping test. Each animal was sys-
tematically handled on a regular basis (i.e., taken by hand from its cage,
put on a table, gently touched, moved from one place to another, and
then, after several minutes of continuous contact with the human hand,
returned to its home cage) for several days before the first assessment.
Forelimb akinesia (Fig. 1) was assessed using a modified version of the
Figure 1. Timeline of the experimental plan. Twoweeks after the lesionwith 6-OHDA, ratswere testedwith the DA agonist apomorphine (APO) and then selected for successful lesions, based on
the number of contraversive turns, counted with automatic rotometers for 40 min as previously reported. Two months after the lesion, the animals were randomly allotted in five different
experimentally treated groups: Control group (saline, i.p.); I Pramipexole group (0.1mg/kg, i.p., twice a day); II Pramipexole group (0.3mg/kg, i.p., twice a day); III Pramipexole group (1mg/kg, i.p.,
once a day); and L-DOPA group (10mg/kg, twice a day). At the end of chronic pharmacological treatment, animalswere killed by cervical dislocation and coronal corticostriatal sliceswere prepared.
After30 min, the slices were used for electrophysiological recordings.
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stepping test (Paille´ et al., 2007). Briefly, the experimenter firmly sus-
pended the rat’s hindquarters while it supported its weight on its fore-
limbs. Then, the experimenter moved the rat backwards along the table
(0.9 m in 5 s) three times consecutively per session. All the sessions were
video recorded to allow the number of adjusting steps to be counted
afterward by an investigator blinded to the state of the rat (i.e., 6-OHDA-
lesioned or sham-operated). For each session, the total score calculated
was the sum of the number of adjusting steps observed in the three tests
(for the contralateral paw). The sessions took place between 2:30 and 4:30
P.M. 1 week before surgery and 2 weeks after surgery (just before the
apomorphine-induced rotation test and during the pharmacological
treatments).
L-DOPA and DA agonist treatment. Two months after the lesion,
6-OHDA full-lesioned rats (n 205)were allotted into three experimen-
tal groups. The first group was treated with L-DOPA (n 50, 10 mg/kg
L-DOPAplus 6mg/kg benserazide, twice daily, i.p.). The second group of
6-OHDA rats (n  155) received the non-ergot D2-like agonist
pramipexole [0.1 (n 35) and 0.3 (n 41) mg/kg twice daily, i.p., and 1
mg/kg (n  60) injected once daily, i.p.]. The last group of 6-OHDA-
lesioned rats (n 19) was used for control electrophysiological record-
ings. Since we have noted, in a pilot experiment, that treatment with the
higher dose of pramipexole 1 mg/kg injected once daily was able to in-
duce in rats a prolonged turning behavior, with severe loss of weight, we
chose to treat the animals chronically only once daily with this dosage.
Drug-induced abnormal involuntary movements (AIMs, or dyskine-
sia) were recorded on alternate days three times a week using a validated
AIM scale in rat, and were classified into three subtypes: axial, limb, and
orolingual AIMs, as previously described (Cenci et al., 1998; Lundblad et
al., 2002; Picconi et al., 2003; Gardoni et al., 2006). Each of these subtypes
was scored on a severity scale from 0 to 4. Total AIMs score for each
session was obtained by summing the monitoring period scores. Two-
way ANOVA and Tukey’s HSD post hoc test were used for statistical
comparison when appropriate.
Electrophysiology. The preparation and maintenance of coronal corti-
costriatal slices have been described previously (Calabresi et al., 1992;
Picconi et al., 2003). Corticostriatal coronal slices, 240 m thickness,
were prepared. A single slice was transferred to a recording chamber and
submerged in a continuously flowing artificial CSF (ACSF) solution
(room temperature, 3 ml/min) gassed with 95% O2/5% CO2. The com-
position of the ACSF solution was as follows (inmM): 126 NaCl, 2.5 KCl,
1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 11 glucose, and 25 NaHCO3.
Whole-cell patch-clamp recordings. Whole-cell patch-clamp recordings
were performed from medium spiny neurons (MSNs) visualized using in-
frared differential interference contrast microscopy in the dorsal striatum
(Eclipse FN1, Nikon) (Bagetta et al., 2011). Recordings were made with a
Multiclamp 700B amplifier (Molecular Devices), using borosilicate glass pi-
pettes (outer diameter, 1.5 mm; inner diameter, 0.86mm) pulled on a P-97
Puller (Sutter Instruments). Pipette resistances ranged from 3.5 to 5 M.
Membrane currents were continuously monitored and access resistance
measured in voltage clamp was in the range of 5–30 M before electronic
compensation (60–80% routinely used). Current–voltage relationships
were obtained by applying steps of current of 50 pA in both depolarizing
and hyperpolarizing direction (from400 to 400 pA, 500ms). For sponta-
neous EPSCs (sEPSCs), pipettes were filled with an internal solution con-
taining the following (inmM): 120CsMeSO3, 15CsCl, 8NaCl, 0.2 EGTA, 10
HEPES, 2 Mg-ATP, 0.3 Na-GTP, 10 tetraethylammonium, and 5 QX-314
[N-(2,6-dimethylphenylcarbamoylmethyl) triethylammonium bromide],
pH7.2,withCsOH.Picrotoxin(50M)wasaddedtoblockGABAAcurrents.
MSNs were clamped at the holding potential (Vh) of 70 mV. Data were
acquired with pClamp 10.2 (Molecular Devices); current was filtered at 0.1
kHz, digitized at 200 s using Clampex 10.2 (gap-free mode), analyzed of-
fline using the automatic detection, and subsequently checkedmanually for
accuracy. The threshold amplitude for the detection of an event (5 pA) was
adjusted above root mean square noise level (2–3 pA atVh70mV).
A bipolar stimulating electrode was located intrastriatally, close to the
recording electrode (50–150 m), to evoke glutamate-mediated synap-
tic currents [evoked EPSCs, (eEPSCs)] inMSNs, in the continuous pres-
ence of picrotoxin (50 M). Stimuli were delivered at 0.1 Hz. In this
condition, the evoked potentials were fully blocked by MK-801 or AP-5
(30M) and CNQX (10M). Baseline current level was detected asmean
current value recorded between 10 and 50 ms before electrical stimula-
tion. The maximal current value recorded between 10 and 150 ms after
stimulation was considered as eEPSC peak. eEPSC amplitude was ob-
tained by subtracting the baseline current value from the peak current
value. Only cells that had stable baseline and peak current levels for at
least 10 min before drug application were used for statistical analysis. All
drugs were from Sigma-Aldrich and were applied by switching the con-
trol perfusion to drug-containing solution. Experiments were discarded
if the access resistance varied by20%.
For the NMDAR/AMPAR ratio experiments, MSNs were voltage-
clamped at70 and40 mV to record, respectively, AMPAR-mediated
and NMDAR-mediated EPSCs. The NMDA EPSC component was indi-
viduated by using the kinetic method, considering the peak amplitude at
50 ms after the beginning of the event. The NMDAR/AMPAR ratio was
calculated by dividing the NMDAR peak by the AMPAR peak (Paille´ et
al., 2010). In the experiments with SCH23390, slices were incubated with
the antagonist (10 M) for at least 2 h and then the NMDAR/AMPAR
ratio was recorded.
The rectification pattern of the AMPAR was calculated using voltage-
clamp method (holding level was between70 mV and40 mV). The
rectification index (IR) was calculated by the current–voltage relation-
ship as the ratio of EPSC amplitudes between70 and40 mV.
Data are expressed as means SEM, and Student’s t test and one-way
ANOVA were used for statistical analysis, unless otherwise stated. Dif-
ferences between groups were considered significant when Bonferroni
post hoc test resulted of p 0.05.
Western blot analysis. Western blot analysis was performed in total
homogenate or in Triton-insoluble postsynaptic fractions (TIFs, see be-
low). To check for specificity, three different D3 DA receptor antibodies
were tested and used. The following antibodies were used: polyclonal D3
DA receptor antibodies purchased fromAbcam and Santa Cruz Biotech-
nology (H-50 and H-14); polyclonal GluN2A antibody purchased from
Sigma-Aldrich; monoclonal GluN2B antibody purchased from Neuro-
Mab; polyclonal GluA1 antibody purchased from Merck Millipore;
monoclonal GluA2 antibody purchased from NeuroMab; monoclonal
tubulin antibody purchased from Sigma-Aldrich.
Subcellular fractionation. Subcellular fractionation of striatal tissue was
performed as previously reported withminormodifications (Gardoni et al.,
2006). Striatawere homogenized in ice-cold sucrose 0.32M containing 1mM
HEPES, 1mMMgCl2, 1mM EDTA, 1mMNaHCO3, 0.1 mM PMSF, pH 7.4.
Thehomogenized tissuewas centrifugedat 1000	 g for 5min.The resulting
supernatant (S1) was centrifuged at 13,000	 g for 15min to obtain a crude
membrane fraction (P2 fraction). The pellet was resuspended in buffer con-
taining 75mMKCl and 1%TritonX-100 and centrifuged at 100,000	 g for
1 h. The final pellet, referred to as TIF, was homogenized in a glass-glass
potter in 20mMHEPES and stored at80°C until processing. TIFwas used
instead of the classical postsynaptic density because the amount of the start-
ingmaterialwasvery limited.Allpurificationswereperformed inpresenceof
a complete set of protease (Complete) and phosphatase (PhosSTOP) inhib-
itors (Roche Diagnostics).
Results
Forelimb akinesia after chronic treatment with dopaminergic
drugs: pramipexole vs L-DOPA treatment
Three different doses of pramipexole (0.1mg/kg or 0.3mg/kg, given
twice daily and 1 mg/kg once daily) and one dose of L-DOPA (10
mg/kg plus benserazide 6 mg/kg, twice daily) administered for 3
weeks, were challenged to assess the improvement of motor perfor-
mance in hemiparkinsonian rats and also to study cellular physiol-
ogy in vitro (Fig. 1). From a behavioral point of view, the stepping
test, awell knownmotor task,wasused toassessmotor function.The
scoreswere collected at the beginning of everyweek of treatment. As
showed in Figure 2A, all the rats taking part in the study progres-
sively recovered the use of the right paw (contralateral to the lesion)
(within groupmain factor:F(3,108) 9.55; p 0.001). Comparisons
between baseline and post-treatment scores across the groups
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(Fig. 2A) (group–session interaction: F(3,36) 2.95; p 0.05)
showed similar forelimb akinesia results for the baselines of
the four groups. Only the low dose of pramipexole failed to
show any antiparkinsonian effect in the behavioral paradigm
used (pramipexole 0.1 mg/kg, p  0.05; pramipexole 0.3 mg/
kg, p  0.001; pramipexole 1 mg/kg, p  0.001; L-DOPA, p 
0.001). The forelimb akinesia measured prior the beginning of
the treatment (Fig. 2B, Baseline) was comparable among the
four groups. Interestingly, the higher dose of pramipexole (1
mg/kg) was more effective than chronic L-DOPA treatment
(°p  0.05) in recovering the use of the right paw, but not
statistically different from the 0.3 mg/kg pramipexole dose
(p  0.05).
AIMs induction after chronic treatment with pramipexole
versus L-DOPA
AIMs were recorded on alternate days, three times a week using a
validated rat AIMs scale, as previously described (Cenci et al.,
1998; Lundblad et al., 2002; Picconi et al., 2003; Gardoni et al.,
2006). During the chronic drug treatment period, L-DOPA, but
not pramipexole at the dosages of 0.1 mg/kg and 0.3 mg/kg, in-
duced a gradual development of AIMs affecting the trunk, limb,
and orolingual region (Fig. 3A; group–session interaction:
F(24,280)  3.93, p  0.001, post hoc test p  0.05; #L-DOPA vs
pramipexole 0.1 mg/kg; *L-DOPA vs pramipexole 0.3 mg/kg).
Only the experimental group of 6-OHDA-lesioned rats treated
with the high dosage of pramipexole (1mg/kg) showed abnormal
movements (Fig. 3A). Interestingly, the dyskinetic movements
induced by the higher dosage of pramipexole were signifi-
cantly lower than AIMs induced by L-DOPA (L-DOPA vs
pramipexole 1 mg/kg, §p  0.05).
The analysis of the percentage of PD animals developing
AIMs,measured during every session test (Fig. 3A) and at the end
of the treatment (last session test, Fig. 3B), showed that the ad-
ministration of the low doses of pramipexole was associated with
a lower incidence of AIMs [25% dyskinetic (Dys) rats for the 0.1
mg/kg group; 20% Dys rats for the 0.3 mg/kg group] when com-
pared with the pramipexole high-dose group (70% Dys rats for
the 1 mg/kg group) and the L-DOPA group (65%Dys) (Fig. 3C).
None of the tested drugs induced dyskinetic movements or mo-
tor abnormalities in control sham-operated rats (data not
shown).
Figure2. Restorationof forelimbakinesia after chronic treatmentwithdopaminergic drugs:
pramipexole versus L-DOPA treatment. A, Graph shows the motor effect of the drugs at the
beginning of every week of treatment. All treatments increased the performance in stepping
test, without any overall statistically significant differences. B, Graph shows the therapeutic
effect of pramipexole versus L-DOPA on the forelimb akinesia, measured prior the beginning of
the treatment (Baseline), comparedwith the last session test (End of treatment). Interestingly,
1mg/kg doses of pramipexoleweremore effective than chronic L-DOPA treatment (°p 0.05),
but not statistically different from 0.3 mg/kg pramipexole dose (*p 0.05, ***p 0.001;
Baseline vs End of treatment) (°p 0.05, °°p 0.01 between groups).
Figure 3. Therapeutic doses of pramipexole induced fewer dyskinetic movements than
L-DOPA. A, L-DOPA but not 0.1 mg/kg and 0.3 mg/kg pramipexole induced the progressive
development of AIMs ( post hoc test, p 0.05; #L-DOPA vs pramipexole 0.1mg/kg; *L-DOPA vs
pramipexole 0.3 mg/kg). Pramipexole at the dose of 1 mg/kg induced AIMs. However, AIMs
induced by this high dose of pramipexole were significantly fewer than those triggered by
L-DOPA ( p0.05; §L-DOPAvspramipexole1mg/kg).B, Graph shows thedevelopmentofAIMs
measured at the end of the treatment during the last session test. C, Administration of 0.1
mg/kg and 0.3 mg/kg pramipexole induced AIMs in a lower percentage of animals (25% Dys
rats for the 0.1mg/kggroup; 20%Dys rats for the 0.3mg/kggroup) than after administration of
1 mg/kg pramipexole (70% Dys rats for the 1 mg/kg group) and L-DOPA (65% Dys).
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Spontaneous activity alterations induced by 6-OHDA lesion
recovered after L-DOPA or pramipexole treatment
It has been previously shown that the intrinsic properties of stri-
atal MSNs, such as current-evoked firing discharge and current–
voltage relationship, are not significantly altered by 6-OHDA
lesion and L-DOPA treatment (Picconi et al., 2003). In the pres-
ent study, comparable results were obtained in MSNs recorded
from pramipexole-treated animals (data not shown).
Conversely, compelling evidence suggest that glutamate trans-
mission is dramatically increased after 6-OHDA lesion (Calabresi et
al., 1993; Schwarting andHuston, 1996; Tang et al., 2001; Picconi et
al., 2004; VanLeeuwen et al., 2010) especially in terms of frequency
andamplitudeof sEPSCs.Notably, thesealterationsareovercomeby
the restoration of DA levels through “subchronic” L-DOPA treat-
ment (Picconi et al., 2004).
In the present study, through the administration of two doses
of the D2-like agonist pramipexole (1 mg/kg once daily or 0.3
mg/kg twice daily, for 3 weeks), we further characterized the ef-
fect exerted by DA replacement following chronic L-DOPA treat-
ment on spontaneous excitatory synaptic transmission and the
consequence of the DAergic transmission stimulation. The low-
est dose of pramipexole (0.1 mg/kg twice daily) was discarded
from all the electrophysiological studies due to lack of any ther-
apeutic effect. As reported in Figure 4A,B, both frequency (one-
way ANOVA, F(4,42) 4.184, p 0.01) and amplitude (F(4,42)
6.046, p 0.001) of the glutamatergic sEPSCs were significantly
increased compared with control levels after 6-OHDA lesion
[n 6 6-OHDA vs n 8 control (CTRL), *p 0.05, frequency,
**p 0.01, amplitude]. Interestingly, these parameters were suc-
cessfully rescued to control levels by chronic L-DOPA adminis-
tration (n  14 L-DOPA vs CTRL p  0.05) as well as
pramipexole therapy, with the same efficacy, regardless of the two
different doses used (Fig. 4A–C; n 9 pramipexole 0.3 mg/kg vs
CTRL, p 0.05; n 6 pramipexole 1 mg/kg vs CTRL, p 0.05).
NMDAR/AMPAR ratio alteration after 6-OHDA lesion and
DAergic therapy
Tomeasure postsynaptic responsiveness between the different
groups of animals, AMPAR-evoked eEPSCs (Vh, 70 mV)
were compared with evoked NMDAR currents from the
same cell (and stimulation). This enabled us to calculate an
NMDAR/AMPAR current ratio for each individual neuron. This
parameter provides ameasure of NMDAR activity relative to that
one of AMPAR, regardless of the number of presynaptic afferents
recruited and stimulating electrode positioning.
As reported in Figure 5A, direct comparison with MSNs re-
corded from control rats demonstrated a significant effect of the
lesion in reducing theNMDAR/AMPAR ratio at the postsynaptic
site (one-way ANOVA, F(4,44)  8.88, p  0.0001, n  10
6-OHDA vs n  10 CTRL, post hoc test ***p  0.001). Neither
L-DOPA nor the high dose of pramipexole rescued the physio-
logical ratio of these receptors (n  10 L-DOPA vs 6-OHDA,
p  0.05; n  6 pramipexole 1 mg/kg vs 6-OHDA, p  0.05).
Conversely,MSNs recorded fromanimals treatedwith the low ther-
apeutic dose of pramipexole (0.3 mg/kg) showed a NMDAR/AM-
PARratio comparable to theoneobtained in control condition (n
9 pramipexole 0.3 mg/kg vs CTRL, p 0.05).
Then, in looking for a possible relationship between the altera-
tion of NMDAR/AMPAR ratio in MSNs and the behavioral motor
abnormalities, we analyzed the correlation between individual AIM
scores during the 21 d of treatment with L-DOPA or pramipexole
and the respective ratio of the two receptors. Interestingly, the plot-
ting of individualmeanAIMs score during the treatment against the
individualNMDAR/AMPARratio (Fig. 5C) revealed ahighly signif-
icant correlation between the two variables in the group treatedwith
pramipexole (white circles, pramipexole 0.3 mg/kg; gray circles,
pramipexole 1mg/kg) (n 15, Spearman’s r0.5189, p 0.05)
but not in the group treated with L-DOPA (n 15, Spearman’s r
0.1355, p 0.05).
Figure 4. 6-OHDA-lesion-related alterations in spontaneous activity ofMSNs are rescued by
either chronic L-DOPA or pramipexole treatment. A, B, Bar graphs show the averaged values of
the frequency (A) and amplitude (B) of spontaneous events recorded inMSNs from thedifferent
experimental groups: control (CTRL), 6-OHDA-lesioned rats (6-OHDA), L-DOPA-treated rats, 0.3
mg/kg pramipexole-treated rats, and 1mg/kg pramipexole-treated rats (n 8 CTRL vs n 6
6-OHDA, *p 0.05 frequency, **p 0.01 amplitude; n 14 L-DOPA vs 6-OHDA, #p 0.05
frequency, ###p 0.001 amplitude; n 9 pramipexole 0.3 mg/kg vs 6-OHDA, #p 0.05
frequency, #p0.05amplitude,n6pramipexole 1mg/kgvs6-OHDA, #p0.05 frequency,
#p 0.05 amplitude; one-way ANOVA with Bonferroni comparison). C, Representative traces
fromwhole-cell patch-clamp experiments showing glutamatergic sEPSCs recorded fromMSNs
in control condition (upper trace) and in all the other groups of animals studied.
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Extent of NR2A/NRB subunit ratio in animals treated with
L-DOPA or pramipexole
To further comprehend the mechanisms underlying the alterations
inNMDAR/AMPAR ratio found, we performed amolecular analy-
sis of the TIF to obtain the relative abundance of NMDAR and
AMPAR subunits at the postsynaptic site. It is known that AIMs are
associated with consistent synaptic rearrangement of NMDAR
NR2-type subunits, leading to an increase of NR2A/NR2B subunit
ratio in the postsynaptic compartment (Dunah andStandaert, 2003;
Gardoni et al., 2006). In this respect, we analyzed the effects of the
two doses of theD2-like agonist pramipexole (1mg/kg once daily
or 0.3 mg/kg twice daily) or L-DOPA (10 mg/kg plus benserazide
6mg/kg, twice daily) (n 3 rats for each group) administered for
3 weeks, on the relative abundance of these two regulatory sub-
units of theNMDAR in the TIF. As shown in Figure 6A, we found
a significant increase in the NR2A/NR2B ratio only in dyskinetic
1 mg/kg pramipexole-treated animals (Student’s t test, 6-OHDA
vs pramipexole 1mg/kgDys, *p 0.05; pramipexole 1mg/kgDys
vs pramipexole 1 mg/kg Non Dys, #p  0.05). Interestingly, no
alteration of NMDAR regulatory subunits was observed between
Figure 5. NMDAR/AMPAR ratio reduction after 6-OHDA-lesion and DAergic treatment.
A, Summary plot reporting the significant reduction of NMDAR/AMPAR ratio induced by
6-OHDA lesion; neither L-DOPA treatment nor the higher dose of pramipexole rescues this
parameter to control levels (n  10 6-OHDA vs n  10 CTRL, ***p  0.001; n  10
L-DOPA vs CTRL, **p 0.01; n 9; pramipexole 0.3 mg/kg vs CTRL, p 0.05; n 6,
pramipexole 1 mg/kg vs CTRL, **p 0.01; 6-OHDA vs pramipexole 0.3 mg/kg, ##p
0.01; L-DOPA vs pramipexole 0.3 mg/kg, #p 0.05; pramipexole 1 mg/kg vs pramipexole
0.3 mg/kg, #p 0.05; one-way ANOVA with Bonferroni comparison). B, Representative
traces from whole-cell patch-clamp experiments showing AMPAR-evoked and NMDAR-
evoked currents, recorded at70mV and40mV respectively, in the presence of 50M
picrotoxin. NMDAR component wasmeasured at40mV considering the peak amplitude
after 50 ms from the beginning of the event. C, Plotting of individual mean AIMs score
during the treatment with L-DOPA (filled circles) and pramipexole (open circles) against
the individual NMDAR/AMPAR ratio. Significant correlation between the two variables in
the group treated with pramipexole ( p 0.05) but not in that treated with L-DOPA is
revealed by the linear regression (n 15 L-DOPA, Spearman’s r 0.1355, p 0.05; n
15 pramipexole, Spearman’s r0.5189, p 0.05).
Figure6. Alteration of NR2A/NRB subunit ratio in dyskinetic animals treatedwith L-DOPAor
pramipexole. A, B, 6-OHDA-lesioned animals were treated chronically with 0.3 mg/kg
pramipexole, with 1 mg/kg pramipexole (A), or with L-DOPA (B) and divided into two groups
based on the presence (Dys) or absence (Non Dys) of dyskinesia. Striatal TIFs from the above-
indicated experimental groups were analyzed byWestern blot (wb) analysis with NR2A, NR2B,
and tubulin antibodies (see Materials and Methods). The same amount of proteins was loaded
per lane. Histogram in A shows the quantification of Western blotting experiments as NR2A/
NR2B ratio after normalization on tubulin levels (Student’s t test, 6-OHDA vs pramipexole 1
mg/kg, *p 0.05; pramipexole 0.3 mg/kg Non Dys vs pramipexole 1 mg/kg Dys, #p 0.05;
pramipexole 1 mg/kg Non Dys vs pramipexole 1 mg/kg Dys, #p 0.05). B, Histogram shows
the NR2A/NR2B distribution between parkinsonian and L-DOPA-treated rats (6-OHDA vs
L-DOPA Dys, *p 0.05; L-DOPA Non Dys vs L-DOPA Dys, #p 0.05).
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0.3mg/kg and 1mg/kg pramipexole-treated animals not showing
a dyskinetic behavior (Student’s t test, pramipexole 1 mg/kg Non
Dys vs pramipexole 0.3mg/kgNonDys, p 0.05), thus confirm-
ing the presence of a correlation between induction of AIMs and
increased NR2A/NR2B ratio. Similarly, and in agreement with
previous studies (Gardoni et al., 2006), alteration ofNR2A/NR2B
ratio correlates with onset of dyskinesia also following treatment
with L-DOPA (Fig. 6B, Student’s t test, L-DOPA Non Dys vs
L-DOPA Dys, #p 0.05; 6-OHDA vs L-DOPA Dys, *p 0.05).
However, significant modifications of the AMPAR amount
were not found at the postsynaptic compartment (data not
shown). Nevertheless, we are aware that this latter result does
not exclude a possible modification of the receptor trafficking
to the plasma membrane within the postsynaptic compart-
ment or changes in its activity, which may contribute to
NMDAR/AMPAR ratio alterations.
AMPAR subunit composition is differently affected by
L-DOPA or pramipexole treatment
We then investigated whether, in addition to the different extent
in NMDAR/AMPAR ratio found following DAergic denervation
and replacement, AMPAR subunit modifications might also take
place at glutamatergic synapses. In fact, synapses in MSNs con-
tain a mixed AMPAR population that can undergo a rapid
activity-dependent switch in subtypes. TheGluR2 subunit in par-
ticular is a key determinant of biophysical properties of AMPARs.
In fact, an arginine residue in the pore-lining region makes
GluR2-containing AMPARs impermeable to calcium ions
(Ca2) which thus display a characteristic linear current–voltage
relationship (Pellegrini-Giampietro et al., 1997; Cull-Candy et
al., 2006). In contrast, AMPARs lacking GluR2 subunits are per-
meable to Ca2 and are characterized electrophysiologically by
an inward-rectifying current–voltage relationship. For this pur-
pose, we measured the IR, calculated as the ratio between the
AMPAR-evoked current at 70 mV and at 40 mV, to test the
hypothesis that an exchange in subunit composition and then
Ca2 permeability might occur after DAergic denervation, as
observed in theMPTPmodel of PD (VanLeeuwen et al., 2010). It
is noteworthy that the IR value considerably increased after
6-OHDA lesion and it reached a level of significant difference
compared with control level (Fig. 7A; one-way ANOVA F(4,38)
10.86, ***p 0.001, n 7 6-OHDA vs n 8 CTRL, post hoc test
**p  0.01), suggesting a stronger inward-rectifying current–
voltage relationship, further evident after either L-DOPA treat-
ment or the higher dose of pramipexole (Fig. 7A, n 11 L-DOPA
vs n  8 CTRL, ***p  0.001; n  7 pramipexole 1 mg/kg vs
CTRL, **p 0.01). Interestingly, 0.3mg/kg pramipexole admin-
istered twice daily, representing the therapeutic dose free from
dyskinetic side effects, was able to bring the IR back to control
level (Fig. 7A, n  7 pramipexole 0.3 mg/kg vs CTRL, p  0.05;
pramipexole 0.3mg/kg vs 6-OHDA, ##p 0.01; pramipexole 0.3
mg/kg vs L-DOPA, ###p 0.001).
To evaluate the predictive value of IR on dyskinesia develop-
ment, we investigated the eventual correlation between IR and
the AIMs score as reported in Figure 7B, where a correlation
between IR and AIMs score in the rats treated with either
pramipexole (white circles, pramipexole 0.3 mg/kg; gray circles,
pramipexole 1 mg/kg) or L-DOPA is shown (n  11 L-DOPA,
Pearson’s r  0.0238, p  0.05; n  13 pramipexole, Pearson’s
r 0.7126, p 0.01).
Having found an increased proportion of GluR2-lacking
AMPARs at synaptic level after either DAergic lesion and
L-DOPA or high dose of pramipexole treatment, we examined
whether the modification of AMPAR assemblage affected the
kinetics of the recorded currents at these synapses. The decay
phase of the AMPAR EPSC was best fitted by a single expo-
nential curve at70 mV (Ozawa et al., 1998). In all the groups
Figure 7. Modifications of AMPAR subunit complex after 6-OHDA lesion and pharmacological
treatments. A, Top of the graph shows example of an individual experiment obtained in control
condition to calculate the IR of AMPAR (scale bars, 50ms and 100 pA). In the bottom, the bar graph




mg/kg, #p  0.05; one-way ANOVA with Bonferroni comparison). B, IR values obtained from
pramipexole-treated and L-DOPA-treated rats were correlated with AIM score. The linear regression
revealedasignificantcorrelationbetweenthesetwovariablesamongthepramipexole-treatedgroup
(n 11 L-DOPA, Pearson’s r 0.0238, p 0.05;n 13pramipexole, Pearson’s r 0.7126, p
0.01).C, Decay time constants ofAMPAR, calculatedby fittingwith a single exponential, are summa-
rized in the bar graph.
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recorded, no significant difference was observed in the kinetic
properties, as shown in Figure 7C. This result suggests that
EPSCs displaying different rectification properties may have a
similar decay time course, at least in MSNs.
Alteration of D3R levels in dyskinetic animals treated with
L-DOPA or pramipexole
We hypothesized that the appearance of dyskinetic behavior and
the related synaptic abnormalities after chronic treatment with
L-DOPAor the high dose of pramipexole,might be dependent on
the convergence of these two drugs on D3R-mediated signaling.
The importance of D3R in the emergence of L-DOPA-induced
dyskinesia is still matter of debate (Berthet et al., 2009; Visanji et
al., 2009). However, evidence from several experiments suggests
that a significant D3R overexpression takes place in this condi-
tion (Bordet et al., 2000) and contributes to the overactivity of
D1R pathway.
Interestingly, in dyskinetic animals obtained after chronic
treatment with the high dose of pramipexole as well as in
L-DOPA-treated dyskinetic rats (Fig. 8A), a significant increase of
D3R quantity is detectable (Student’s t test, n  3 rats for each
group; pramipexole 1 mg/kg Non Dys vs pramipexole 1 mg/kg
Dys, ##p 0.01; pramipexole 0.3mg/kgNonDys vs pramipexole
1mg/kgDys, ##p 0.01; L-DOPANonDys vs L-DOPADys, #p
0.05). It is noteworthy that, even the chronic treatmentwith a low
dose of pramipexole can induce the overexpression of D3R com-
pared with control (pramipexole 0.3 mg/kg Non Dys vs CTRL,
**p  0.01). However, this increase is “less severe” when com-
paredwith the levels ofD3R found in dyskinetic animals obtained
with the high dosage. These results further support a central role
for D3R in the emergence of dyskinesia, likely due to its ability of
boosting the D1R pathway.
To further prove this concept, we incubated corticostriatal
slices obtained from dyskinetic animals treated with 1 mg/kg
pramipexole, with the D1R antagonist SCH23390 (10M), for at
least 2 h. The NMDAR/AMPAR ratio was measured in this con-
dition. As expected, this treatment was capable of bringing the
synaptic parameter back to control level (Fig. 8B) (Student’s t
test, n  6 pramipexole 1 mg/kg vs n  5 pramipexole 1 mg/kg
plus SCH23390, **p 0.01). Similar results were obtained with
the IR (data not shown). The time window of 2 h incubation,
chosen as a shorter incubation period, did not affect the
NMDAR/AMPAR ratio (n  4, data not shown). This observa-
tion might suggest that the modification of the synaptic param-
eter is not simply a result of an acute D1R antagonism, but rather
involves a more complex downstream machinery. In fact, a re-
cent experimental work revealed the profound impact of D1 re-
ceptor prolonged activaction/inactivation in the control of
NMDAR and AMPAR subunit arrangement (Vastagh et al.,
2012).
Figure8. Alteration of D3R levels in dyskinetic animals treatedwith L-DOPA or pramipexole.
A, 6-OHDA-lesioned animals were treated chronically with 10 mg/kg L-DOPA, 0.3 mg/kg
pramipexole, or 1mg/kg pramipexole and divided into two groups based on the presence (Dys)
or absence (Non Dys) of dyskinesia. Striatal lysates from the above-indicated experimental
groups were analyzed by Western blot (wb) analysis with D3 antibodies (see Materials and
4
Methods). The same amount of proteins was loaded per lane. Histograms show the quantifica-
tion of wb experiments after normalization on tubulin levels (CTRL vs pramipexole 0.3 mg/kg
Non Dys, **p 0.01; 6-OHDA vs pramipexole 0.3 mg/kg Non Dys, #p 0.05; pramipexole 1
mg/kg Non Dys vs pramipexole 1 mg/kg Dys ##p 0.01; pramipexole 0.3 mg/kg Non Dys vs
pramipexole 1mg/kgDys ##p 0.01; L-DOPANonDys vs L-DOPADys, #p 0.05).B, Bar graph
compares theNMDAR/AMPAR ratio recorded in vitro fromdyskinetic animals after chronic treat-
ment with the high dose of pramipexole, with or without a prolonged incubation of the D1
antagonist SCH23390 (n  6 pramipexole 1 mg/kg vs n  5 pramipexole 1 mg/kg plus
SCH23390, **p 0.01).
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Discussion
The current study provides the first evidence that in an experi-
mental model of PD, a chronic and “mild level” of D2-like recep-
tor stimulation, in addition to its therapeutic action and the
reduced level of dyskinetic movements compared with L-DOPA,
overcomes profound synaptic alterations occurring at striatal
glutamatergic synapses (Calabresi et al., 1993; Picconi et al., 2004;
VanLeeuwen et al., 2010). In fact, chronic treatment with an
intermediate dose (0.3mg/kg twice daily) of pramipexole retunes
the NMDAR/AMPAR ratio imbalance and seems to restore the
correct assemblage of AMPAR subunits at the postsynaptic site as
shown by the normalization of the IR of AMPAR currents.
Our study also provides relevant pathophysiological informa-
tion concerning the role of the increased spontaneous glutama-
tergic activity in the parkinsonian striatum. In fact, while we
confirmed in this study that both the amplitude and the fre-
quency of sEPSCs are increased in this PD model, we also ob-
served as a new finding that both L-DOPA and pramipexole
treatments are able to reverse these synaptic abnormalities re-
gardless the motor side effects produced. This latter observation
indicates that, although changes in the features of sEPSCs repre-
sent a consistent synaptic alteration in PD models, they do not
seem to play a critical role in the control of the dyskinetic
behavior.
Interestingly, changes in glutamate-mediated and DA-
dependent striatal synaptic plasticity have been already impli-
cated in the pathophysiology of LID. In particular, in dyskinetic
animals we have reported lack of depotentiation (reversal of
NMDA-dependent long-term potentiation) (Picconi et al., 2003)
and loss of long-term depression (Picconi et al., 2011), indicating
that chronic L-DOPA treatment inducing dyskinesia impairs the
scaling down of glutamatergic synapses. Here we integrate this
view and propose an additional mechanism further linking ab-
normal involuntary movements triggered by DAergic stimula-
tion to an abnormal glutamatergic transmission.
In fact, we found that chronic L-DOPA, aswell as the high dose
of pramipexole, fails to rescue the physiological NMDAR/
AMPAR ratio and both these treatments induce a similar degree
of dyskinesia. Surprisingly, however, we observed that the abnor-
mal NMDAR/AMPAR ratio was correlated to high AIM score in
the pramipexole-treated group but not in the L-DOPA-treated
group. In fact, the lowdose of pramipexole (0.3mg/kg), free from
dyskinetic side effects, was associated with a NMDAR/AMPAR
ratio similar to that seen in control animals. In contrast, the high
dose of the drug, inducing elevated AIMs scores, resulted in ab-
normal values of this parameter in the neurons recorded from
dyskinetic animals. The strict relationship between high AIMs
score and abnormal NMDAR/AMPAR ratio was completely lost
in the L-DOPA-treated group where, even in those subjects not
showing dyskinesia, an “abnormal” change in NMDAR/AMPAR
ratio was observed. One possible mechanism explaining this ap-
parently contrasting resultmight be the absence of selectivity that
L-DOPA has for D1 and D2 receptors. Furthermore, one could
also speculate that, because almost all subjects chronically treated
with L-DOPApresumablywill develop dyskinesia over time (sim-
ilarly to PD patients), the alteration of the NMDAR/AMPAR
ratio simply precedes the appearance of abnormal behavior in
non-dyskinetic animals.
Among the increasing number of D2-like receptor agonists,
pramipexole is currently the most prescribed for PD treatment,
showing a preferential affinity also for the DA-D3 receptor sub-
type (D3R) and lacking affinity for D1 andD5 receptors (Gerlach
et al., 2003). In the striatum, D3Rs, once activated, exert a syner-
gistic effect on D1R-mediated transmission through direct in-
tramembrane interaction (Fiorentini et al., 2008; Marcellino et
al., 2008). Pramipexole binding to D3R boosts D1R function,
which explains, in part, the antiparkinsonian efficacy of this com-
pound. On the other hand, the activation of D2R by pramipexole
reduces indirect pathway neuron excitability, which physiologi-
cally acts in the opposite direction to the direct pathway inmove-
ment control. The synergy of these two actions may account for
the efficacy of this compound in the treatment of PD symptoms
but also for the side effects induced by the high dose of this
agonist.
D3 receptors comprise 1% of DA receptors in the caudate
putamen in physiological condition, suggesting that the abun-
dance of the D1R–D3R heteromer is also low. However, in path-
ological condition, such as in L-DOPA-induced dyskinesia, this
fine regulation is impaired. Thus, D3R overexpression has been
observed in striatal neurons of the direct pathway associated with
defect in D1R internalization, which was counteracted by a D3R
antagonist, suggesting a role of the D3R in immobilizing the D1R
at the plasmamembrane (Fiorentini et al., 2008;Marcellino et al.,
2008).
In line with these results, we believe that the alteration of the
NMDAR/AMPAR ratio is likely dependent on dysregulation of
D1R activation. Pramipexole, in fact, might indirectly enable the
activity of D1R throughD1R–D3R heteromerization and, at high
dosage, it could determine sensitization of D1R-mediated path-
way, as observed following L-DOPA-treatment. This concept is
supported by evidence showing that a high dose of pramipexole
massively increases the expression of D3R in dyskinetic animals.
Our results suggest that a moderate dose of pramipexole, free
from dyskinetic side effects, restores the NMDAR/AMPAR ratio,
possibly allowing a finely balanced activation of D1R, as sug-
gested by the intermediate increase of D3R. However, sustained
activation of D3R obtained with a high dose of pramipexole,
could have detrimental effects on both motor performance and
synaptic circuitry via the abnormal indirect activation of the D1-
dependent transmission.
It is well known that alterations inNMDAR/AMPAR ratio can
be related to changes in activity and/or abundance of NMDAR or
AMPAR, or to both events. This latter condition seems to be
more probable in the present scenario. In fact, modifications of
the abundance ofNMDAR subunits (Gardoni andDi Luca, 2006;
Gardoni et al., 2012), as well as abnormal phosphorylation of
striatal NMDAR and AMPAR subunits, have been pointed out in
several experimental studies in animal models of LID (Dunah et
al., 2004; Santini et al., 2007).
Interestingly, by showing changes in the NR2A/NR2B subunit
ratio, we provide for the first time evidence that the dyskinetic phe-
notype emerging after chronic treatment with a D2R agonist (i.e.,
pramipexole) is also accompanied by a perturbed NMDAR assem-
blage at the postsynaptic compartment, and that this action is a
function of the dose used for the treatment.
In addition, here we show that both parkinsonism and dys-
kinesia are associated with a switch of AMPAR subunit com-
position within glutamatergic synapses. In particular, we
demonstrated an increased IR in MSNs, suggesting a possible
abnormal insertion of GluR2-lacking AMPARs at corticostria-
tal synapses. In fact, this rise in IR indicates that, in these condi-
tions, a switch toward a nonlinear voltage–current relationship
occurs within glutamatergic synapses and stems from a major
availability of Ca2-permeable receptors (i.e., GluR2-lacking
AMPARs). This particularAMPAR subtype iswidely expressed in
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the CNS, where it contributes to synaptic transmission and
changes in synaptic efficacy (Isaac et al., 2007). Nevertheless,
compelling evidence indicates that several neurological disor-
ders, such as cerebral ischemia, amyotrophic lateral sclerosis,
pain, and epilepsy, are associated with alterations in GluR2 func-
tion (Cull-Candy et al., 2006). This result is in agreement with
previous data demonstrating that dopaminergic lesion as well as
dyskinetic condition are associated with increased activity of
calcium-permeable AMPAR due to hyperphosphorylation of
GluR1 subunit (Santini et al., 2007).
Here we show that, in striking contrast to L-DOPA, the inter-
mediate dose of pramipexole, which has antiparkinsonian effects
and is associated with reduced AIMs score, restores the AMPAR
subunit composition, in addition to rescuing the physiological
ratio in the two glutamatergic receptors. In fact, this moderate
dose of pramipexole is able to correct the IR that was altered after
6-OHDA lesion. However, the higher dose of pramipexole is un-
able to rescue this parameter to control levels.
Among the possible mechanisms implicated in the increased
availability of GluR2-lacking receptors at the postsynaptic site,
those that might be essential include the abnormal NMDAR ac-
tivity and Ca2 influx in L-DOPA-induced dyskinesia. In fact,
several lines of evidence show that NMDAR signaling is essential
in GluR2 subunit internalization in physiological condition
(Hayashi and Huganir, 2004).
Thus, because Ca2 permeability of AMPARs depends on the
absence of GluR2 subunits (Mishina et al., 1991), increased in-
sertion of GluR2-lacking receptors obviously triggers “abnor-
mal” cellular Ca2 dynamics, related downstream pathways, and
eventually “pathological” synaptic plasticity in a vicious cycle that
leads to the amplification of NMDAR dysfunction.
In accordance with our results, a recent paper fromKobylecki
et al. (2010), using a selective GluR2-lacking AMPAR antagonist
(IEM-1460), which was able to significantly reduce the induction
and expression of dyskinesia, revealed the pivotal role of these
receptors in LID induction and expression.
In conclusion, the findings of the present work cast further
light on the cellularmechanisms that subtend the development of
dyskinesia during treatment with L-DOPA and D2-like receptor
agonists. Moreover, our results confer further emphasis to the
role of therapeutic strategies alternative to L-DOPA, such as those
represented by D2R/D3R agonists family.
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